US2009205062A1PendingUtilityA1

Caspase-9 deficient animals and the use thereof

Assignee: KUIDA KEISUKEPriority: Jun 2, 1998Filed: Dec 7, 2007Published: Aug 13, 2009
Est. expiryJun 2, 2018(expired)· nominal 20-yr term from priority
A01K 2227/105A01K 2267/03A01K 2217/05C12N 15/8509A61K 38/00A01K 67/0276C12N 9/6475A01K 2217/075C12N 9/6472A61K 2039/505A61P 43/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to genetically manipulated animals that are deficient in the expression of Casapse-9, a protein involved in programmed cell death. The invention further relates to methods for preventing specific types of cell death associated with Caspase-9 activation.

Claims

exact text as granted — not AI-modified
1 . A genetically altered animal defective in Caspase-9 expression. 
     
     
         2 . The genetically altered animal according to  claim 1 , wherein said animal is a mouse. 
     
     
         3 . A method of producing a genetically altered animal defective in Caspase-9 expression comprising the steps of:
 a. providing an isolated DNA sequence comprising a genomic DNA sequence encoding a Caspase-9 that does not contain the pentapeptide motif QACXG, wherein “X” is arginine of glycine;   b. introducing said DNA sequence into an embryonic stem cell under conditions that cause said DNA sequence to stably integrate into a chromosome of said stem cell;   c. incorporating said stem cell into a blasotcyst of said animal to produce a chimeric animal;   d. breeding said chimeric animal to an animal that expresses functional Caspase-9 to produce an animal heterozygous for functional Caspase-9;   e. interbreeding said animals heterozygous for functional Caspase-9 expression to produce said animal deficient in Caspase-9 expression.   
     
     
         4 . The method according to  claim 3 , wherein said DNA sequence additionally comprises a selectable marker gene. 
     
     
         5 . The method according to  claim 4 , wherein said marker gene is a neo gene. 
     
     
         6 . A method of treating or preventing developmental abnormalities, nerve cell death, smooth or cardiac muscle degeneration or cell death associated with viral infection in an animal comprising the step of administering to said animal a composition comprising a molecule which inhibits either the expression of Caspase-9 or the activity of Caspase-9. 
     
     
         7 . The method according to  claim 6 , wherein said molecule is selected a monoclonal or polyclonal antibody specific for Caspase-9, an oligonucleotide that specifically hybridizes to Caspase-9 DNA so as to prevent transcription of functional Caspase-9 mRNA, an oligonucleotide that specifically hybridizes to Caspase-9 mRNA to as to prevent expression of Caspase-9 or a ribozyme that specifically cleave Caspase-9 mRNA.

Join the waitlist — get patent alerts

Track US2009205062A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.